Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 164Breast Neoplasms 111Colorectal Neoplasms 77Neoplasms 65Lung Neoplasms 61Pancreatic Neoplasms 56Stomach Neoplasms 52Neoplasm Metastasis 51Ovarian Neoplasms 45Rectal Neoplasms 43Esophageal Squamous Cell Carcinoma 38Esophageal Neoplasms 38Head and Neck Neoplasms 34Squamous Cell Carcinoma of Head and Neck 32Leukemia, Myeloid, Acute 32Recurrence 26Triple Negative Breast Neoplasms 25Small Cell Lung Carcinoma 24Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Glioblastoma 23Colonic Neoplasms 23Uterine Cervical Neoplasms 22Nasopharyngeal Carcinoma 22Lymphoma 21Lymphoma, Non-Hodgkin 20Fallopian Tube Neoplasms 20Prostatic Neoplasms 17Melanoma 17Sarcoma 16Leukemia 16

Interventions

pembrolizumab 4Pemetrexed 4Carboplatin 4Gemcitabine 3Bevacizumab 3tusamitamab ravtansine 2Vinorelbine 2Ramucirumab 2Erlotinib Hydrochloride 2Docetaxel 21-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 2vistusertib 1vandetanib 1telomerase reverse transcriptase p572Y, human 1spartalizumab 1sotorasib 1sintilimab 1olaparib 1necitumumab 1icotinib 1durvalumab 1dacomitinib 1capivasertib 1aumolertinib 1Radiosurgery 1Platinum 1Paclitaxel 1MLN 8237 1LY3023414 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Non-small Cell Lung Cancer Metastatic × Drug Therapy × Clear all
NCT03656094 2019-12-09

Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors

Samsung Medical Center

Phase 2 Unknown
98 enrolled
Thoracic

Non-small Cell Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡